Search the Newsreel

Trading the Move, Not the Narrative: (VRDN) Edition

This article provides an AI-generated analysis for Viridian Therapeutics Inc. (NASDAQ: VRDN), highlighting mixed sentiment and choppy conditions across different time horizons. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, along with multi-timeframe signal …

Viridian Therapeutics, Inc. Stock 12‑Month Price Target Cut to $36.07, Implies 58% Upside

The average 12-month price target for Viridian Therapeutics, Inc. (VRDN) stock has been lowered to $36.07 from $36.81 by 15 analysts, suggesting a potential upside of approximately 58% from its August 12 closing price. Despite the target cut, the consensus rating from 17 covering …

Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 22%

Analysts have significantly revised down Viridian Therapeutics' 2026 revenue estimates by 22% to US$22 million, representing a 70% reduction from the past 12 months. Concurrently, per-share loss forecasts have increased to US$3.97. Despite a recent 10% stock price increase, the updated consensus suggests a …

VRDN Stock Records Biggest Single Day Gains In 45 Months – And It’s Not Just Due To A Better-Than-Feared Q1 Loss

Is Viridian Therapeutics' (VRDN) Widening Losses Despite Higher Revenue Reframing Its Risk Reward Profile?

HC Wainwright Has Negative Forecast for VRDN Q3 Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Viridian Therapeutics (NASDAQ:VRDN) recently reported quarterly results showing revenues significantly better than expected, though statutory losses per share were in line with forecasts. Despite the strong revenue performance, analysts have subsequently cut their revenue outlook for 2026 and increased their loss per share expectations, …

Viridian Therapeutics (VRDN) Stock Rises Despite Deepening Losses And Cash Burn

RBC Adjusts Viridian Therapeutics PT to $36 From $35, Maintains Outperform Speculative Risk Rating

RBC has increased its price target for Viridian Therapeutics (VRDN) to $36 from $35, while reiterating an Outperform Speculative Risk rating. The company currently holds an average analyst rating of "buy" with a mean price target of $36.75.

Viridian Therapeutics (NASDAQ:VRDN) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS

State Street Corporation (NASDAQ: VRDN) discloses 5.5% Viridian Therapeutics ownership

State Street Corporation has reported a 5.5% ownership stake in Viridian Therapeutics, Inc. (VRDN), held through various subsidiaries including State Street Global Advisors entities. This significant holding comprises 6,124,976 shares of common stock, with shared voting and dispositive power, indicating a notable institutional position …

Truist Financial Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price

Viridian Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Viridian Therapeutics Inc has released its earnings summary for the quarter that concluded on June 30. The report details the company's financial performance during this period, providing key insights into its operational results. This information is available through Refinitiv, with additional access offered via …

Viridian Therapeutics 2Q 2026: Revenue $284K, EPS $(1.05) — 10-Q Summary

Viridian Therapeutics reported its second-quarter 2026 results, showing early commercial revenue of $284K following FDA approval of Veligrotug (Lumvoa). The company experienced a wider net loss of $127.1M, reflecting its transition from an R&D to a commercial organization. Key highlights include the U.S. launch …

Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says

RBC Capital Markets forecasts "minimal" revenue growth for Viridian Therapeutics (VRDN) in the second half of the year. The report, published by MT Newswires, indicates that a more meaningful inflection in revenue is expected after this period. Access to the full article requires a …

Viridian Therapeutics earnings missed by $0.02, revenue topped estimates

Press Release: Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Viridian Therapeutics has released its second quarter 2026 financial results, alongside an update on recent business developments. This announcement provides insights into the company's financial performance and strategic progress during the quarter.

Viridian Reports Continuation of Massive Sulphides at Kraken Main; First Assays Pending

OTTAWA, Ontario, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Assays are now pending from the first diamond drill holes completed as part of Viridian Metals Inc.'s (CSE: VRDN) (OTCQB: VIRMF) 2026 drill program at the Kraken project in Labrador. The initial assay submission includes the …

Earnings Flash (VRDN) Viridian Therapeutics, Inc. Reports Q2 Revenue $284,000

Viridian Therapeutics reports Q2 2026 net loss of $127.1M, cash $981.5M after Lumvoa FDA approval

Viridian Therapeutics reported a Q2 2026 net loss of $127.1 million, with $981.5 million in cash, cash equivalents, and marketable securities. This report follows the FDA approval and U.S. commercial launch of Lumvoa for thyroid eye disease on June 26, 2026, and the company …

Viridian Therapeutics (VRDN) Earnings Date and Reports 2026

First Trust Advisors LP Grows Stock Holdings in Viridian Therapeutics, Inc. $VRDN

First Trust Advisors LP significantly increased its stake in Viridian Therapeutics (NASDAQ:VRDN) by 151.5% in the first quarter, now holding 301,529 shares valued at $5.9 million. The clinical-stage biopharmaceutical company, which develops antibody therapies for rare diseases like thyroid eye disease, reported a first-quarter …

(VRDN) Volatility Zones as Tactical Triggers

This article provides an AI-driven analysis of Viridian Therapeutics Inc. (NASDAQ: VRDN), highlighting neutral readings in shorter time horizons and a weak bias in the long term. It identifies an exceptional short setup with a significant risk-reward ratio and outlines three distinct trading strategies: …

How Positive Elegrobart REVEAL-1 Phase III Data Could Impact Viridian Therapeutics (VRDN) Investors

Viridian Therapeutics reported positive topline results from its Elegrobart REVEAL-1 phase III trial for Graves' ophthalmopathy, planning a Biologics License Application in early 2027. This, alongside the recent LUMVOA approval, strengthens the company's position in the autoimmune eye disease market, despite continued unprofitability and …

Graves Ophthalmopathy Market Expected to Witness Rapid Expansion at a CAGR of 9% During the Forecast Period (2026-2036), Driven by the Recent Approval of Viridian's LUMVOA and the Launch of Emerging Therapies | DelveInsight

The Graves' ophthalmopathy market is expected to witness steady growth over the coming years, driven by the rising prevalence of autoimmune thyroid disorders, improved disease awareness, and earlier diagnosis. Additionally, the recent approval of LUMVOA has heightened competition in the Graves' ophthalmopathy market. Furthermore, …

Viridian Therapeutics (VRDN) Expected to Announce Quarterly Earnings on Wednesday

Price to earnings forward of Viridian Therapeutics, Inc. – LSE:0K1R

This article provides the "Price to earnings forward" value for Viridian Therapeutics, Inc. (LSE:0K1R). The core data presented is a single numerical value for this financial metric, alongside its change and percentage change. The article focuses solely on this specific financial data point for …

Viridian Therapeutics Inc (VRDN) Institutional Confidence

Viridian Therapeutics Inc (VRDN) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 8.27% quarter-over-quarter, reaching 112.73%. Steven Cohen is the largest institutional shareholder, holding 365.59K shares and increasing …

Viridian Therapeutics Inc (VRDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides an incomplete revenue breakdown for Viridian Therapeutics Inc (VRDN), stating that much of the relevant data has not yet been disclosed by the company. It does, however, show a regional revenue figure for the United States at $70.85 million with a …

Viridian Therapeutics Inc (VRDN) Income Statement

This article provides a detailed quarterly and annual income statement for Viridian Therapeutics Inc (VRDN), covering various financial metrics from total revenue to basic and diluted earnings per share. It also includes frequently asked questions about how to interpret these statements and key metrics …

VRDN|Viridian Therapeutics Inc|Price:19.270|Chg%:+0.010

This article provides a comprehensive stock analysis of Viridian Therapeutics Inc (VRDN) by TradingKey. It highlights the company's strong fundamentals, significant growth potential, and relatively fair valuation within the Biotechnology & Medical Research industry. The analysis notes high institutional ownership, a "Buy" rating from …

Viridian Therapeutics stock trades around recent lows as cash runway and thyroid eye trial data shap

Viridian Therapeutics (VRDN) stock is trading around recent lows, influenced by its cash runway and upcoming thyroid eye disease trial data. The biotech company is advancing its lead investigational product for thyroid eye disease, having reported positive mid-stage clinical trial data, but faces challenges …

Viridian Therapeutics Inc (VRDN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Viridian Therapeutics Inc (VRDN), highlighting its current valuation score of 6.83, which ranks it 295 out of 386 in the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -4.82 and mentions that relevant …